CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors
Expert Opin Investig Drugs
.
2022 Sep;31(9):875-879.
doi: 10.1080/13543784.2022.2108588.
Epub 2022 Aug 3.
Authors
Christopher Moertel
1
,
Francisco Martinez-Puerta
1
,
Grace G Elizabeth Pluhar
2
,
Maria Graciela Castro
3
,
Michael Olin
1
Affiliations
1
Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
2
Department of Veterinary Clinical Sciences, University of Minnesota Twin Cities, Minneapolis, MN, USA.
3
Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.
PMID:
35920338
PMCID:
PMC9997597
DOI:
10.1080/13543784.2022.2108588
No abstract available
Keywords:
CD200; Immune checkpoint; glioblastoma; immunotherapy.
Publication types
Editorial
MeSH terms
Brain
Brain Neoplasms* / pathology
Glioblastoma* / drug therapy
Humans
Immunotherapy
Grants and funding
R01 NS105556/NS/NINDS NIH HHS/United States
R01 NS122165/NS/NINDS NIH HHS/United States
R37 NS094804/NS/NINDS NIH HHS/United States
U01 NS052465/NS/NINDS NIH HHS/United States